These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

398 related items for PubMed ID: 23276450

  • 1. Small-molecular, non-peptide, non-ATP-competitive polo-like kinase 1 (Plk1) inhibitors with a terphenyl skeleton.
    Mita Y, Noguchi-Yachide T, Ishikawa M, Hashimoto Y.
    Bioorg Med Chem; 2013 Feb 01; 21(3):608-17. PubMed ID: 23276450
    [Abstract] [Full Text] [Related]

  • 2. Design, synthesis, and evaluation of non-ATP-competitive small-molecule Polo-like kinase 1 (Plk1) inhibitors.
    Chen DX, Huang J, Liu M, Xu YG, Jiang C.
    Arch Pharm (Weinheim); 2015 Jan 01; 348(1):2-9. PubMed ID: 25430493
    [Abstract] [Full Text] [Related]

  • 3. Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells.
    Chapagai D, Ramamoorthy G, Varghese J, Nurmemmedov E, McInnes C, Wyatt MD.
    J Med Chem; 2021 Jul 22; 64(14):9916-9925. PubMed ID: 34210138
    [Abstract] [Full Text] [Related]

  • 4. Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1.
    Berg A, Berg T.
    Chembiochem; 2016 Apr 15; 17(8):650-6. PubMed ID: 26662918
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors.
    Sato Y, Onozaki Y, Sugimoto T, Kurihara H, Kamijo K, Kadowaki C, Tsujino T, Watanabe A, Otsuki S, Mitsuya M, Iida M, Haze K, Machida T, Nakatsuru Y, Komatani H, Kotani H, Iwasawa Y.
    Bioorg Med Chem Lett; 2009 Aug 15; 19(16):4673-8. PubMed ID: 19589677
    [Abstract] [Full Text] [Related]

  • 9. Aromatic diacylhydrazine derivatives as a new class of polo-like kinase 1 (PLK1) inhibitors.
    Sun J, Lv PC, Guo FJ, Wang XY, Xiao-Han, Zhang Y, Sheng GH, Qian SS, Zhu HL.
    Eur J Med Chem; 2014 Jun 23; 81():420-6. PubMed ID: 24859762
    [Abstract] [Full Text] [Related]

  • 10. Design and synthesis of highly selective, orally active Polo-like kinase-2 (Plk-2) inhibitors.
    Bowers S, Truong AP, Ye M, Aubele DL, Sealy JM, Neitz RJ, Hom RK, Chan W, Dappen MS, Galemmo RA, Konradi AW, Sham HL, Zhu YL, Beroza P, Tonn G, Zhang H, Hoffman J, Motter R, Fauss D, Tanaka P, Bova MP, Ren Z, Tam D, Ruslim L, Baker J, Pandya D, Diep L, Fitzgerald K, Artis DR, Anderson JP, Bergeron M.
    Bioorg Med Chem Lett; 2013 May 01; 23(9):2743-9. PubMed ID: 23522834
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery.
    Strebhardt K, Becker S, Matthess Y.
    Expert Opin Drug Discov; 2015 Jan 01; 10(1):1-8. PubMed ID: 25263688
    [Abstract] [Full Text] [Related]

  • 13. Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE.
    Craig SN, Baxter M, Chapagai D, Stafford JM, Nurmemmedov E, Altomare D, Wyatt MD, McInnes C.
    Eur J Med Chem; 2022 Jan 05; 227():113926. PubMed ID: 34735919
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pinning down the polo-box domain.
    Lee KS, Idle JR.
    Chem Biol; 2008 May 05; 15(5):415-6. PubMed ID: 18482691
    [Abstract] [Full Text] [Related]

  • 17. Development of Bifunctional Inhibitors of Polo-Like Kinase 1 with Low-Nanomolar Activities Against the Polo-Box Domain.
    Scharow A, Knappe D, Reindl W, Hoffmann R, Berg T.
    Chembiochem; 2016 Apr 15; 17(8):759-67. PubMed ID: 26634982
    [Abstract] [Full Text] [Related]

  • 18. Identification of novel polo-like kinase 1 inhibitors by a hybrid virtual screening.
    Lu S, Sun SL, Liu HC, Chen YD, Yuan HL, Gao YP, Yang P, Lu T.
    Chem Biol Drug Des; 2012 Aug 15; 80(2):328-39. PubMed ID: 22583481
    [Abstract] [Full Text] [Related]

  • 19. Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis.
    Gilmartin AG, Bleam MR, Richter MC, Erskine SG, Kruger RG, Madden L, Hassler DF, Smith GK, Gontarek RR, Courtney MP, Sutton D, Diamond MA, Jackson JR, Laquerre SG.
    Cancer Res; 2009 Sep 01; 69(17):6969-77. PubMed ID: 19690138
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.
    Reindl W, Yuan J, Krämer A, Strebhardt K, Berg T.
    Chem Biol; 2008 May 01; 15(5):459-66. PubMed ID: 18482698
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.